AU2006250120A1 - Regeneration of a chromatography matrix - Google Patents

Description

WO 2006/126942 PCT/SE2006/000599 REGENERATION OF A CHROMATOGRAPHY MATRIX Technical field The present invention relates to chromatography, and more specifically to a process of 5 regenerating chromatography matrices to restore their performance. The invention also encompasses a kit for performing such regeneration, as well as a multi-step process comprising several cycles of regeneration according to the invention. Background 10 The term chromatography embraces a family of closely related separation methods based on two mutually immiscible phases brought into contact, wherein one phase is stationary and the other one is mobile. One area wherein chromatography has recently become of great interest is in the biotechnological field, such as for large-scale economic production of novel drugs and diagnostics. Generally, proteins are produced by cell culture, either 15 intracellularly or secreted into the surrounding medium. Since the cell lines used are liv ing organisms, they must be fed with a complex growth medium, containing sugars, amino acids, growth factors, etc. Separation of the desired protein from the mixture of compounds fed to the cells and from other cellular components to a sufficient purity, e.g. for use as a human therapeutic, poses a formidable challenge. 20 Conventionally, cells and/or cell debris has been removed by filtration. Once a clarified solution containing the protein of interest has been obtained, its separation from the other components of the solution is usually performed using a combination of different chro matographic techniques. These techniques separate mixtures of proteins on the basis of 25 their charge, degree of hydrophobicity, affinity properties, size etc. Several different chromatography matrices are available for each of these techniques, allowing tailoring of the purification scheme to the particular protein involved. As in all process technology, an important aim is to keep the production costs low. Thus, 30 in order to reduce the number of steps required to obtain a product from a cell culture or lysate, improved chromatographic techniques have been presented. Similarly, chroma- WO 2006/126942 2 PCT/SE2006/000599 tography matrices are when possible reused. However, since each use of a chromatogra phy matrix will leave certain traces of the operation just performed, many different cleaning protocols are available for restoring the matrix into its original form. Com monly known materials that need to be removed are e.g. non-eluted proteins and protein 5 aggregates. Another important concern within the pharmaceutical industry is the pres ence of potentially hazardous materials, such as virus, endotoxins etc, which originates from the cell culture and which need to be removed to avoid cross-contamination be tween batches. 10 The most commonly used cleaning is a simple wash with buffer, such as the equilibra tion buffer. Such washing can only be used to restore the matrix a limited number of times. For a more efficient cleaning, treatments with acid and/or base are frequently used, each removing acid and base-sensitive contaminants respectively. In order to even more efficiently restore the matrix, an alkaline protocol known as Cleaning In Place 15 (CIP) is commonly used with many matrices. The standard CIP involves treatment of the matrix with 1M NaOH, pH 14. Such harsh treatment will efficiently remove undesired fouling such as by protein aggregates and the like, but may on the other hand impair some chromatography matrices. For example, many affinity matrices, wherein the ligands are proteins or proteinaceous, cannot withstand standard CIP, at least not while 20 maintaining their original properties. For example, one of the most commonly used af finity chromatography matrices for purification of antibodies comprises Protein A ligands, but such matrices needs to be cleaned under milder conditions than conventional CIP in order to maintain selectivity and binding capacity. In this context, it is understood that the cleaning is closely related to the lifetime of the chromatography matrix. For ex 25 ample, a sensitive matrix may be cleaned with standard CIP, if a reduced performance is acceptable. The performance of column packed with a chromatography matrix is easily verified using well known methods. Brorson et al (Kurt Brorson, Janice Brown, Elizabeth Hamilton, Kathryn E. Stein in 30 Journal of Chromatography A, 989 (2003) 155-163: Identification of protein A media performance attributes that can be monitored as surrogates for retrovirus clearance dur- WO 2006/126942 3 PCT/SE2006/000599 ing extended re-use") describes how Protein A media can be re-used after cleaning with 6M urea or 6 M guanidine hydrochloride, which are known as milder cleaning buffers than sodium hydroxide. It is concluded that column performance was stable even after more than 300 cycles. However, use of urea involves certain drawback. For once, it is a 5 relatively costly chemical at present. Secondly, due to its fertilising effect, it cannot be readily disposed of without taking certain precautions to obey with legislation. Thus, there is still a need in this field of alternative cleaning protocols for chromatogra phy matrices, especially for use with more labile materials. 10 Brief description of the present invention The present invention relates to problems associated with the re-use of separation matri ces, preferably chromatography matrices. Illustrative such problems are fouling of packed chromatography matrices and the building up of back pressure during operation. 15 thus, one aspect of the present invention is a process of regenerating a separation matrix. This may be achieved using a protocol comprising at least one reducing regeneration, as defined in the appended claims. A specific aspect of the invention is a process of regenerating a chromatography matrix 20 which comprises labile ligands and/or support materials. Another aspect of the present invention is the use of a regenerated chromatography ma trix in the purification of target molecules, such as proteins. 25 Other aspects and advantages of the present invention will appear from the detailed de scription that follows. Brief description of drawings Figure 1 shows a comparison of selected chromatograms during lifetime study including 30 reducing regeneration according to the invention.

WO 2006/126942 4 PCT/SE2006/000599 Figure 2 shows the host cell protein concentration in the elution peaks from an extended cleaning protocol including reducing regeneration according to the invention. Figure 3 shows the yield (%) versus cycle number from an extended cleaning protocol according to the invention. 5 Figure 4 shows the peak broadening of elution peaks obtained after reducing regenera tion according to the invention (triangles, lower curve) and without wash with reducing agent (filled circles, upper curve). Figure 5 shows the leakage of Protein A during a control experiment as described in the Experimental part. 10 Definitions The term "regeneration" of a chromatography matrix means herein to a process which substantially restores the matrix to its original strength or properties. 15 The term "chromatography matrix" means herein a stationary phase for use in chroma tography, also known as a resin. A chromatography matrix is commonly comprised of a porous or non-porous solid support, to which a plurality of ligands have been coupled, directly or via spacers or extenders. The term "ligand" is used herein as conventionally used within the field of chromatogra 20 phy, i.e. for a group or a compound, which comprises at least one functional group. The term "alkaline-labile" means herein sensitivity to alkaline concentrations corre sponding to pH values in the region of 10-14. The term "proteinaceous ligands" means herein ligands that comprise proteins and/or protein-like molecules such as peptides. 25 The term "eluent" means herein a liquid capable of releasing target molecules from a chromatography matrix. The releasing action may e.g. be provided by the pH and/or the conductivity of the eluent. The term "target molecules" is used herein for any specific molecule or kind of molecule that adsorbs to the chromatography matrix in question, and embraces compounds and 30 cells as well as actual molecules. The term "break-through capacity" is defined as the amount of target molecules than can be applied to a chromatography matrix, normally packed in a column, before break- WO 2006/126942 5 PCT/SE2006/000599 through of target molecules in the effluent. The term QB10%, is commonly used, and re fers to the point when the effluent concentration reaches 10% of the initial sample con centration. 5 Detailed description of the invention In a first aspect, the present invention relates to a process of regenerating a separation matrix, comprising (a) providing a matrix from which an adsorbed sample has been eluted; (b) reducing regeneration by contacting said matrix with a reducing agent; 10 (c) alkaline regeneration by contacting the matrix with an alkaline solution; (d) equilibration of the matrix; wherein the regeneration steps are carried out in any order of sequence. In one embodi ment, the order of steps is the above. 15 In the present process, the separation matrix is advantageously a chromatography matrix, which has been used in a chromatography process. In one embodiment, a sample from which one or more target molecules are to be isolated is combined with a suitable buffer to form a mobile phase, which is subsequently contacted with the matrix during a suit able period of time for said target(s) to adsorb. In an alternative embodiment, the sample 20 comprises buffer and can be contacted with the matrix as such. As is well known, con ventional chromatography matrices commonly retain a certain amount of unbound mate rials, which are easily removed by washing with a suitable liquid, preferably by washing with a buffer. After having removed such unbound materials, elution is commonly per formed by adding an eluent, which is capable of releasing the adsorbed target mole 25 cule(s) from the matrix. Thus, in one embodiment, the present process of regenerating a separation matrix com prises (a) adsorption of at least one target molecule by contacting a mobile phase compris 30 ing target molecule(s) with a matrix; (b) removal of unbound material by washing the matrix; WO 2006/126942 6 PCT/SE2006/000599 (c) elution of target molecule(s) by contacting the matrix with eluent; (d) reducing regeneration by contacting said matrix with a reducing agent; (e) alkaline regeneration by contacting the matrix with an alkaline solution; and (f) equilibration of the matrix; 5 wherein the regeneration steps are carried out in any order of sequence. In one embodi ment, the order of steps is the above. As discussed above, the separation matrix is advan tageously a chromatography matrix. As the skilled person in this field will easily realise, each added solution, such as eluent, 10 solution comprising the reducing agent, buffers etc are advantageously withdrawn from the matrix before the next one is added. In the most advantageous embodiment of the process, the chromatography matrix is present in a chromatography column, such as an axial or radial chromatography column. In one embodiment, the liquids are added and withdrawn as in batch adsorption chromatography. In an alternative embodiment, the 15 liquids are passed across the column by pumping; by gravity; or by use of a pressure dif ferential. In an advantageous embodiment, the present process comprises acidic regeneration by contacting the chromatography matrix with an acidic solution at any time after elution 20 but before equilibration of the chromatography matrix. In a specific embodiment, the acidic regeneration is carried out after the reducing regeneration. As the skilled person in this field will recognize, adding a reducing agent in a chroma tographic process may entail the risk of retained reducing agent in the matrix, which 25 could potentially harm or contaminate the target molecule(s). However, by performing at least one of acidic and alkaline regeneration subsequent to the addition of reducing agent, such risk is minimized or even eliminated. Thus, in one embodiment, the acidic and alkaline regenerations are carried out subsequent to the reducing regeneration. In a specific embodiment, the order of steps after elution is reducing regeneration; acidic re 30 generation; alkaline regeneration; and equilibration.

WO 2006/126942 7 PCT/SE2006/000599 The present process may be utilised with any kind of chromatography matrix, provided the support and the ligands are capable of withstanding the reducing regeneration. Thus, the process is applicable to regeneration of matrices for ion exchange, such as cation ex change and anion exchange; hydrophobic interaction chromatography (HIC) matrices; 5 immobilised metal affinity chromatography (IMAC) matrices; and affinity matrices, such as with proteinaceous ligands. However, chromatography matrix comprising bonds or groups that are susceptible to reduction should be avoided. For example, some bonds such as disulfide bonds which 10 will be readily reduced should be avoided. In one embodiment of the process, the chro matography matrix comprises proteinaceous ligands substantially devoid of reducible bonds, such as disulfide bonds. In this context, "substantially devoid of' means that the number of disulfide bonds is sufficiently low for the ligand not to be impaired by the reducing regeneration. In a specific embodiment, the ligands of the chromatography ma 15 trix do not comprise any such reducible bonds. The present invention is especially advantageously used for regenerating a chromatogra phy matrix which is sensible to the conventionally used regeneration protocol using harsh alkaline conditions, commonly using 1M NaOH. Thus, in an advantageous em 20 bodiment, the ligands are alkaline-labile. As is well known, due to their composition, proteinaceous ligands are usually sensitive to harsh alkaline conditions, such as 1M NaOH. Thus, in an advantageous embodiment, the proteinaceous ligands comprise Pro tein A. As is well known, Protein A, which presents a peptidic backbone and no disulfide bonds, is a commonly used protein ligand due to its superior specificity to antibodies. 25 Protein A separation matrices are commercially available, such as the product line Mab SelectTM (GE Healthcare, Uppsala, Sweden). As the skilled person will readily recognize, the discussion above regarding ligands sus ceptible to reduction applies equally to the support material. The above-discussed 30 ligands may be coupled to any well known kind of porous or non-porous support, which may be in the form of particles, such as essentially spherical particles, a monolith, filter, WO 2006/126942 8 PCT/SE2006/000599 membrane, surface, capillaries, etc. In one embodiment, the support is prepared from a native polymer, such as cross-linked carbohydrate material, such as agarose, agar, cellu lose, dextran, chitosan, carrageenan, gellan, alginate etc. To obtain high adsorption ca pacities, the support is preferably porous, and ligands are then coupled to the external 5 surfaces as well as to the pore surfaces. Such native polymer supports are easily prepared according to standard methods, such as inverse suspension gelation (S Hjert6n: Biochim Biophys Acta 79(2), 393-398 (1964). Alternatively, the support is prepared from a synthetic polymer, such as cross-linked 10 synthetic polymers, e.g. styrene or styrene derivatives, divinylbenzene, acrylamides, acrylate esters, methacrylate esters, vinyl esters, vinyl amides etc. Such synthetic poly mers are easily produced according to standard methods; see e.g. "Styrene based poly mer supports developed by suspension polymerization" (R Arshady: Chimica e L'Indus tria 70(9), 70-75 (1988)). 15 In yet an alternative embodiment, the support of the chromatography matrix which is regenerated according to the invention is prepared from an inorganic material, such as glass or silica. In a specific embodiment, the support is comprised of controlled pore glass (CPG) particles. 20 Immobilising ligands to anyone of the above-discussed supports is also easily performed by the skilled person in this field following well-known methods; see e.g. Immobilized Affinity Ligand Techniques, Hermanson et al, Greg T. Hermanson, A. Krishna Mallia and Paul K. Smith, Academic Press, INC, 1992. 25 However, chromatography matrices suitable for regeneration according to the present invention are also readily available from commercial sources, such as the SepharoseTM and SourceTM series (GE Healthcare Bio-Sciences, Uppsala, Sweden), which include ion exchangers and hydrophobic interaction chromatography matrices. In an advantageous 30 embodiment, the chromatography matrix is MabSelectTM or MabSelect XtraTM (GE Healthcare Bio-Sciences, Uppsala, Sweden).

WO 2006/126942 9 PCT/SE2006/000599 In an advantageous embodiment, the adsorption of target molecule(s) is advantageously carried out to a chromatography matrix equilibrated with a buffer. Such buffers are read ily available from commercial sources and easily selected by the skilled person in this field depending on the nature of the chromatography matrix and target molecule(s). 5 In an advantageous embodiment, the washing of the chromatography matrix to which target molecule(s) have been adsorbed is carried out by contacting the chromatography matrix with a buffer. The buffer may be any suitable buffer, such as the same kind used for equilibration. 10 In an advantageous embodiment, the elution is carried out by a stepwise or continuous pH gradient. Such gradients, and useful methods for providing them e.g. by buffer blend ing, are well known in this field. The eluent is easily selected by the skilled person in this field depending on the nature of the chromatography matrix and target molecule(s). 15 The reducing regeneration may be performed using any suitable reducing agent, prefera bly in the form of a solution, such as DTE, DTT, mercaptoethanol, L-cysteine, and thioglycerol, which are all readily commercially available. In one embodiment, the re ducing agent comprises one or more thiols. In a specific embodiment, the reducing agent 20 comprises thioglycerol. The optimal pH for reducing regeneration will be dependent on the reducing agent selected, and will commonly be in a range of 8-8.5. Thus, in one em bodiment, the reducing regeneration is carried out at alkaline pH. The acidic regeneration may be performed using any suitable acid, such as acetic acid. In 25 one embodiment of the present process, the acidic regeneration is carried out at pH be low 3. As the skilled person in this field will recognize, to obtain the most advantageous acidic regeneration, some processes may require certain conductivity. Thus, in one em bodiment, the acidic regeneration is carried out with a solution comprising salt. Illustra tive salts are e.g. sodium sulphate (Na 2

SO

4 ) and sodium chloride (NaCl). 30 WO 2006/126942 10 PCT/SE2006/000599 The alkaline regeneration may be performed using any suitable alkaline agent, such as sodium hydroxide of a suitable concentration. In one embodiment of the present process, the alkaline regeneration is carried out at pH in the range of 10-14, such as 11-13. In one embodiment, the pH is 11-12. In another embodiment, the pH is 12-13. As the skilled 5 person in this field will recognize, to obtain the most advantageous alkaline regeneration, some processes may require certain conductivity. Thus, in one embodiment, the alkaline regeneration is carried out with a solution comprising salt. Illustrative salts are e.g. as exemplified above in the context of the acidic regeneration. 10 The present invention also encompasses the chromatography matrix regenerated using the process according to the invention. Consequently, in a further aspect, the invention relates to the use of a regenerated chromatography matrix according to the invention for the isolation, purification and/or separation of antibodies. Thus, the present chromatog raphy matrix is useful to recover monoclonal or polyclonal antibodies, such as antibodies 15 originating from mammalian hosts, such as mice, rodents, primates and humans, or anti bodies originating from cultured cells such as hybridomas. In a specific embodiment, the antibodies recovered are immunoglobulin G (IgG). In the present context, it is to be un derstood that the tern "antibodies" also includes antibody fragments and any fusion pro tein that comprises an antibody or an antibody fragment. The antibodies recovered ac 20 cording to the present invention are useful as drugs, such as personalised medicine which comprise an active ingredient designed for a specific individual, or in conventional medicine. The antibodies isolated according to the invention are also useful in research and in the diagnostic field. Alternatively, the regenerated chromatography matrix of the invention may be used to remove undesired molecules, such as antibodies, from a de 25 sired liquid. In a further aspect, the invention relates to a kit for regenerating a chromatography ma trix, which kit comprises, in separate compartments, at least one reducing agent; at least one alkaline buffer; and written instructions for its use. In one embodiment, the kit com 30 prises at least one acidic buffer. In another embodiment of the present kit, the reducing agent is an aqueous stable solution containing a reducing agent, such as WO 2006/126942 11 PCT/SE2006/000599 thioglycerol. Suitable buffers and reducing agents may be as discussed above. In a spe cific embodiment, the present kit comprises, in separate compartments, a packed chro matography column; at least one reducing agent; at least one alkaline buffer; and written instructions for its use. 5 In a final aspect, the invention relates to a method for isolating at least one target mole cule, which method comprises (a) adsorption of target molecules by contacting a mobile phase comprising target molecule(s) with a separation matrix; 10 (b) preferably before the break-through capacity is reached in step (a), removal of unbound material by washing of the matrix; (c) elution of target molecule(s) by contacting the matrix with an eluent; (d) after re-equilibration of the matrix; repeating steps (a)-(c); (d) reducing regeneration by contacting said matrix with a reducing agent; 15 (e) alkaline regeneration by contacting the matrix with an alkaline solution; (f) equilibration of the matrix; and, optionally, repeating steps (a)-(f); wherein the regeneration steps are carried out in any order of sequence. In one embodi ment, the order of steps is the above. In an advantageous embodiment, the separation matrix is a chromatography matrix, as discussed above. 20 In an advantageous embodiment, the method comprising acidic regeneration by contact ing the chromatography matrix with an acidic solution at any time after elution but be fore equilibration of the chromatography matrix. The details described above in the con text of the regeneration process according to the invention may also apply to the present 25 aspect of the invention, such as buffers, reducing agents etc. In one embodiment of the method, steps (a)-(c) are repeated 2-5 times, optionally includ ing (d). This embodiment is especially useful to purify a target molecule from a large feed of fermentation broth, which requires more than one run on the chromatography 30 matrix to recover all target molecules.

WO 2006/126942 12 PCT/SE2006/000599 In an advantageous embodiment, steps (a)-(c) are carried out any number of times, such as 1-5 times, followed by the regeneration protocol according to the invention in any one of the above-discussed embodiments. The equilibration will be included if required. The regenerated chromatography matrix may then be used again e.g. in accordance with steps 5 (a)-(c), such as 1-5 times, followed by a second regeneration protocol. As the skilled per son in this field will realise, the process may be adapted in any way suitable for the spe cific purpose and target, including one, two or more regeneration protocols in between which the actual chromatography procedure is carried out. 10 Thus, in a specific embodiment, the whole method, i.e. steps (a) to (f) are repeated 2-500 times, such as 2-400, advantageously 2-300 and more advantageously 2-200 times. In a specific embodiment, the whole method is repeated 2-200 times. As the person skilled in this field will understand, steps (a)-(c) may be repeated a number of times, such as 2, 3, 4, 5 or more times, without the more thorough regeneration of the subsequent steps. How 15 often the regeneration of the invention, starting with step (d), is required will depend on the kind of separation matrix, target molecule and the level of impurities as well as on the required performance. Thus, the protocol will easily be optimised for each specific case by the skilled person in this field. As discussed above in the Background section, running the regeneration is especially useful when changing from one feed to another, or 20 in case the fouling of the matrix impairs its performance to a non-acceptable extent. In the most advantageous embodiment, the target molecules are proteins, such as anti bodies, for example monoclonal antibodies. The use of the recovered antibodies is as described above. In an advantageous embodiment, the chromatography matrix comprises 25 proteinaceous ligands, preferably protein A ligands. Detailed description of the drawings Figure 1 shows a comparison of selected chromatograms during lifetime study including reducing regeneration according to the invention, as described in example 1 below. More 30 specifically, cycle 6 (shown in blue), cycle 21 (shown in red), cycle 40 (shown in brown) WO 2006/126942 13 PCT/SE2006/000599 and cycle 60 (shown in green) illustrates how little the separation matrix is affected by repeated cleaning protocols according to the invention. Figure 2 shows the host cell protein concentration in the elution peaks from an extended cleaning protocol including reducing regeneration according to the invention. The reduc 5 ing agent is 1-thioglycerol, and the concentration of host cell protein (CHOP) is in ppm. As appears from Figure 2, the concentration of host cell protein is essentially unchanged, which means that the separation matrix is still capable of removing undesired compo nents even after a large number of regeneration cycles. Figure 3 shows the yield (%) versus cycle number from an extended cleaning protocol 10 according to the invention, wherein the reducing agent is 1-thioglycerol. As expected from a well functioning cleaning protocol, the yield remains substantially unaltered. Figure 4 shows the peak broadening of elution peaks obtained after reducing regenera tion according to the invention (triangles, lower curve) as described in example 3 below; and a conventional cleaning protocol without wash with reducing agent (filled circles, 15 upper curve). As appears from Figure 4, the conventional cleaning protocol leads to peak broadening much sooner than the protocol according to the invention. Figure 5 shows the leakage of Protein A from an affinity matrix during a control experi ment as described in the Experimental part below. As appears from Figure 5, the leakage does not present any substantial increase even after a large number of cycles, which 20 means that the binding of Protein A ligands to the separation matrix is not affected to any substantial degree by the cleaning protocol according to the invention. EXPERIMENTAL PART 25 The following examples are provided for illustrative purposes only, and should not in any way be construed as limiting the scope of the invention as defined by the appended claims.

WO 2006/126942 14 PCT/SE2006/000599 Materials / Investigated units Instruments Chromatography system AKTATM Explorer 10, HJ E-10, with UNICORN v. 4.11 5 Spectrophotometer Ultrospec 3000pro, no 839 Columns HR 5/5, GE Healthcare Bio-Sciences Chemicals/other 10 Acetic acid, Merck, cat. no. 1.00063, p.a. Benzyl alcohol, Merck, cat. no. 1.09626, p.a. HCl, Merck, cat. no. 1.00317, p.a. Na-citrate, Merck, cat. no. 1.06448, p.a. NaCl, Merck, cat. no. 1.06404, p.a. NaN 3 , BDH, cat. no. 103692K, Merck 15 cat. no. 6688 NaOH, Merck, cat. no. 1.06469, p.a. Na 2

SO

4 , Merck, cat. no. 1.06649, p.a. Tris, Merck, cat. no. 1.08382, p.a. 1-thioglycerol 90, from GE Healthcare Bio-Sciences (raw material supply) 30-2507-00 KCl, Merck, cat no 4936.1000 20 EDTA, anhydrous, SIGMA Water: MilliQ Filters: 1.2 Rm, 0.45 pm, 0.22 pm, Millipore Resins 25 MabSelecXtraTM Buffers Equilibration buffer: 25 mM Tris, 0.15 M NaCl, pH 7.4 Elution buffer: 100 mM acetic acid, pH 3.6 Neutralisation buffer: 1 M Tris pH 9.0 (collected fractions in test tubes) WO 2006/126942 15 PCT/SE2006/000599 Acidic regeneration buffer. 1 M acetic acid, 50 mM Na 2

SO

4 Wash (reducing agent) 100 mM 1-thioglycerol, 25 mM TRIS, 0.15 M NaCl, 25 mM KCl, 1 mM EDTA pH 8.5 Alkaline regeneration solution: 50 mM NaOH, 0.5 M Na 2

SO

4 5 Storage buffer: 2 % Benzyl alcohol, 50 mM Na-citrate, pH 5.0 Samples In this example, feed containing fusion protein expressed in Chinese hamster ovary (CHO) cells was used. The expression of protein was carried out following well known methods. The feed contained 0.48 mg/mL of the fusion protein. 10 Polyclonal human IgG, Gammanorm, was obtained from Octapharma AB. Analyses The protein A and host cell protein content (CHOP) was determined in the eluate pools of selected cycles by. ELISA. 15 Example 1: Column packing HR 5/5 column were filled with 4 M NaCl. A packing tube (HR 16) was connected, and was filled with 20% gel slurry in ~ 0.2 M NaCl. Packing was then performed in Milli Q water at 3 ml/min for 3 min. The packing tube was then disconnected, and a top adaptor 20 was lowered towards the gel surface. After additional packing at 3 ml/min, the adaptor was adjusted 1 mm into the bed. Packing was then continued at 1 ml/min for 20 minutes. Packing performance (i.e. plate number and asymmetry) was evaluated by injection of 100 pl 2% acetone at a flow rate of 0.35 mL/min. The acceptance criteria for the column packing were an asymmetry between 0.8 - 1.33 and number of theoretical plates > 2000 25 N/m. Example 2: Purification protocol according to the invention The method is summarised in table 1 below. The buffer compositions are found in sec tion Materials/Investigated units above. The UV was detected at 280 nm. 30 WO 2006/126942 16 PCT/SE2006/000599 Table 1: A cleaning protocol according to the invention Step Amount Flow (cm/h) Buffer Comment Equilibration 6 CV 300 Equilibration Load 15-18 mg/ml* 206 CHO supernatant 6 mi residence time, load to 15-18 mgfmL media Wash 6 CV 300 Equilibration Wash 5 CV 300 25 mM TRIS pH 8.0 Elution varied 300 Elution Startlstop collect at 300 mAU Reducing re 6 CV** 300 Reducing buffer 100 mM 1-thioglycerol*** Acid regener 3 CV 206 Strip Wash I CV 206 Equilibration Basic regenE 3 CV 103 CIP solution 12 mi residence time Wash 0.5 CV 103 Equilibration 12 mi residence time, performed every two cycles 2Storae 3 CV 103 Storane 12 min residence time, performed eve two c l es *The sample load was decreased to 15 mg/mi, i.e. 82% Of QB,lo%. In addition a control experiment was performed with human gG in equilibration buffer as described below. 5 ** A control experiment was performed with 0 CV, i.e. without the reducing regenera tion according to the invention. iNew 1-thioglycerol solution was prepared every day. 10 Example 3: Investigation of eluate Neutralisation of eluate and absorbance measurement The eluate was collected in test tubes to which 100 of neutralisation buffer had been added. The eluate was diluted (1:20) in equilibration buffer. The concentration of the sample solution was determined at 280 hn in a spectrophotometer and calculated ac 15 cording to Lambert Beer's law. The average value of the absorbance was used for con centration determination. Protein A leakage Neutralized eluate was measured by ELISA as described in Steind F and et al. A simple method to quantify staphylococcal protein A in the presence of human or animal IgG in 20 various samples. Jwmmunol Meth (2000) 235, 6 1-9. Frontal analysiswith pure fusion protein Frontal analysis was performed according to well known methods. The breakthrough capacity (QB10%) was calculated according to 25 WO 2006/126942 17 PCT/SE2006/000599 QBiO% = (Vlo%-Vo)Co/Vc were V1% = applied sample volume at 10% breakthrough, Vo = void volume, Co = sample con centration (mg/ml) and Vc = geometric total volume (ml). 5 Results example 3 A lifetime study using regeneration with 1-thioglycerol was performed for 60 cycles. A selection of chromatograms is presented in figure 1. As can be seen, the chromatograms are quite similar, even though the volume of the elution peaks gradually increased. The 10 total peak broadening was about 7 % for 40 cycles and 10% for 60 cycles (figure 4, tri angles). This is a significant improvement compared to the standard protocol (figure 4, filled circles). Results from measurements of host cell protein levels (CHOP) in the elution peaks are 15 shown in fig. 2. No significant changes could be observed in the CHOP level throughout the study. The yield was relatively stable (>95%) for 60 cycles. Slightly decreased values were ob tained after cycle 37, but no specific trend could be observed (figure 3). The lower val 20 ues occurred directly after change to a new bottle of feedstock, and are probably caused by variation in protein concentration. As a control, frontal analysis with pure fusion pro tein was performed after 55 cycles. The result revealed that the breakthrough capacity (QB,10%) was unaltered compared to the initial capacity (i.e. 18 mg/ml **) (results not shown). 25 The column performance in this study, using HR 5/5 columns, was maintained after 55 cycles (table 2). Table 3: Column performance before and after 55 purification cycles. 30 Packing performance (i.e. plate number and asymmetry) was evaluated by injection of 100 pl 2% acetone at a flow rate of 0.2 mL/min.

WO 2006/126942 18 PCT/SE2006/000599 Column Asymmetry Number of theoretical plates New 1,11 2367 After 55 cycles 1,19 2668 Example 4: Comparative examples 5 Control experiment 1: With and without reducing regeneration A control experiment was performed for 26 cycles by use of the same method as above, but without wash with reducing agent (i.e. without reducing regeneration). The result clearly shows that broadening of the elution peaks is much more serious and accelerated (figure 4). Thus, 10% peak broadening is obtained already after 15 cycles (compared to 10 60 cycles of 1-thioglycerol). The total peak broadening after 26 cycles was about 20%. Control experiment 2: Protein A leakage 70 cycles was performed with the same method as above, but human IgG (28 mg/ml) was loaded to the column instead of fusion protein-containing feed. The Protein A leak 15 age was very low (i.e. s;8 ppm), and no increase in leakage levels could be observed (figure 5, table 3). Table 3. Control experiment 2 - Protein A leakage Protein A leakage 20 Cycle no ng/mi ppm 0 0 0,0 1 78,9 7,1 2 85,15 8,0 4 98,65 6,7 5 77 5,8 12 61,4 4,2 21 31,9 2,9 25 32,05 2,5 30 28,35 2,6 35 39,95 4,4 25 35 39,55 4,4 40 40,1 4,7 45 38,15 4,7 50 37,9 4,2 55 38,1 4,2 60 51,7 5,7 65 58,7 6,2 69 34,8 3,7 70 29,2 3,2

Claims (29)

1. A process of regenerating a separation matrix comprising (a) providing a separation matrix from which an adsorbed sample has been eluted; (b) reducing regeneration by contacting said matrix with a reducing agent; 5 (c) alkaline regeneration by contacting the matrix with an alkaline solution; (d) equilibration of the matrix; wherein the regeneration steps are carried out in any order of sequence.

2. A process of regenerating a separation matrix comprising (a) adsorption of at least one target molecule by contacting a mobile phase compris 10 ing a target molecule(s) with a separation matrix; (b) removal of unbound material by washing the matrix; (c) elution of target molecule(s) by contacting the matrix with an eluent; (d) reducing regeneration by contacting said matrix with a reducing agent; (e) alkaline regeneration by contacting the matrix with an alkaline solution; and 15 (f) equilibration of the matrix; wherein the regeneration steps are carried out in any order of sequence.

3. A process according to claim 1 or 2, further comprising acidic regeneration by con tacting the matrix with an acidic solution at any time after elution but before equilibra tion of the matrix. 20

4. A process according to claim 3, wherein the acidic regeneration is carried out after the reducing regeneration.

5. A process according to any one of the preceding claims, wherein the order of steps after elution is reducing regeneration; acidic regeneration; alkaline regeneration; and equilibration. 25

6. A process according to any one of the preceding claims, wherein steps (a)-(c) are carried out 1-5 times, such as 2-5 times.

7. A process according to any one of the preceding claims, wherein the separation matrix comprises proteinaceous ligands, which are coupled to a support and which are substan tially devoid of disulfide bonds. 30

8. A process according to claim 7, wherein the proteinaceous ligands comprise Protein A WO 2006/126942 20 PCT/SE2006/000599

9. A process according to any one of the preceding claims, wherein the separation matrix has been equilibrated with a buffer before the adsorption.

10. A process according to any one of the preceding claims, wherein the washing is car ried out by contacting the matrix with a buffer. 5

11. A process according to any one of the preceding claims, wherein the elution is car ried out by adding an eluent comprising a stepwise or continuous pH gradient.

12. A process according to any one of the preceding claims, wherein the reducing regen eration is carried out at alkaline pH.

13. A process according to any one of the preceding claims, wherein the reducing agent 10 comprises one or more thiols.

14. A process according to claim 13, wherein the reducing agent comprises thioglycerol.

15. A process according to any one of the preceding claims, wherein the acidic regenera tion is carried out at pH below 3.

16. A process according to any one of the preceding claims, wherein the acidic regenera 15 tion is carried out with a solution comprising salt.

17. A process according to any one of the preceding claims, wherein the alkaline regen eration is carried out at pH in the range of 10-13.

18. A process according to any one of the preceding claims, wherein the alkaline regen eration is carried out with a solution comprising salt. 20

19. A separation matrix regenerated as defined in any one of claims 1-18.

20. Use of a separation matrix according to claim 19 for the isolation, purification or separation of antibodies.

21. A kit for regenerating a separation matrix, which kit comprises, in separate com partments, at least one reducing agent; at least one alkaline buffer; and written instruc 25 tions for its use.

22. A kit according to claim 21, which comprises at least one acidic buffer.

23. A kit according to claim 21 or 22, wherein the reducing agent is an aqueous stable solution containing a reducing agent.

24. A method for isolating at least one target molecule, which method comprises 30 (a) adsorption of target molecules by contacting a mobile phase comprising target molecule(s) with a separation matrix; WO 2006/126942 21 PCT/SE2006/000599 (b) preferably before the break-through capacity is reached in step (a), removal of unbound material by washing of the matrix; (c) elution of target molecule(s) by contacting the matrix with an eluent; (d) after re-equilibration of the matrix; repeating steps (a)-(c); 5 (e) reducing regeneration by contacting said matrix with a reducing agent; (f) alkaline regeneration by contacting the matrix with an alkaline solution; (g) equilibration of the matrix; and, optionally, repeating steps (a)-(f); wherein the regeneration steps are carried out in any order of sequence.

25. A method according to claim 24, further comprising acidic regeneration by con 10 tacting the matrix with an acidic solution at any time after elution but before equili bration of the matrix.

26. A method according to claim 24 or 25, wherein steps (a)-(c) are repeated 2-5 times.

27. A method according to any one of claims 24-26, which method is repeated 2-100 15 times.

28. A method according to any one of claims 24-27, wherein the target molecules are proteins, such as antibodies.

29. A method according to any one of claims 24-28, wherein the matrix comprises proteinaceous ligands, preferably protein A ligands. 20